Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509357 | 0.86 | GAA (0.43) | KMT2AALDH1A1KCNMA1RAB9ANPC1 | |
| SCHEMBL2704988 | 0.86 | RECQL (0.50) | POLBRORCKMT2AKDM4EALDH1A1 | |
| SCHEMBL19088631 | 0.86 | POLB (0.47) | POLBRORCKMT2AKDM4EALDH1A1 | |
| SCHEMBL2705242 | 0.79 | SMN1; SMN2 (0.59) | POLBKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3586573 | 0.79 | KDM4E (0.49) | RORCKDM4EALDH1A1KCNMA1HIF1A | |
| SCHEMBL27877492 | 0.77 | CA12 (0.59) | POLBRORCKMT2ARAB9ANPC1 | |
| SCHEMBL10995760 | 0.75 | KCNMA1 (0.51) | KMT2AALDH1A1KCNMA1RAB9ANPC1 | |
| SCHEMBL15473715 | 0.75 | POLB (0.40) | POLBRORCKDM4EALDH1A1RAB9A | |
| SCHEMBL18713981 | 0.74 | KMT2A (0.58) | POLBRORCKMT2AKDM4EALDH1A1 | |
| SCHEMBL3218274 | 0.72 | CSF1R (0.43) | POLBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017513-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017513-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017513-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170190706-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170190706-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170190706-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20140357622-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357622-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357622-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8653064-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653064-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653064-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2536279-A1 | CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6-METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE | Millennium Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20110245234-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245234-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245234-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2011103089-A1 | CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6--METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103089-A1 | CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6--METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245234-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | AURKB, AURKA, AURKC | POLB 1728/4885RORC 1924/4885KMT2A 852/4885 |
| US-20170190706-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | AURKB, AURKA, AURKC | POLB 1728/4885RORC 1924/4885KMT2A 852/4885 |
| US-20140357622-A1 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE | AURKB, AURKA, AURKC | POLB 1728/4885RORC 1924/4885KMT2A 852/4885 |
| US-10017513-B2 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | AURKA, AURKB, AURKC | POLB 1260/4885RORC 1607/4885KMT2A 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.